Summary of trials
| Trial | NORAM8 | CYCAZAREM9 | MEPEX10 | CYCLOPS7 |
|---|---|---|---|---|
| Disease stage | Early systemic | Mild–moderate renal | Severe renal | Mild–moderate renal |
| Remission induction | MTX+OCS/poCYC+OCS | poCYC+OCS | ivMP+poCYC+OCS vs PE+poCYC+OCS | ivCYC+OCS vs poCYC+OCS |
| Remission maintenance | MTX+OCS or poCYC+OCS | poCYC+OCS vs AZA+OCS | AZA+OCS | AZA+OCS |
CYCAZAREM, randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis; CYCLOPS, randomised trial of daily oral versus pulsed cyclophosphamide for the treatment of ANCA-associated vasculitis; MEPEX, randomised trial of adjunctive treatment for severe glomerulonephritis in ANCA-associated systemic vasculitis, plasma-exchange versus intravenous methylprednisolone; NORAM, efficacy of methotrexate versus cyclophosphamide in the treatment of ‘non-renal’ Wegener's granulomatosis.
AZA, azathioprine; ivCYC, intravenous cyclophosphamide; poCYC, oral cyclophosphamide; ivMP, intravenous methylprednisolone; MTX, methotrexate; OCS, oral corticosteroids; PE, plasma exchange.